Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Panel Embraces Sanofi Diabetes Combo, Shuns 'Pen' Devices

Executive Summary

While the FDA's Endocrinologic and Metabolic Drugs Advisory Committee backed approval of Sanofi SA's fixed-ratio combination type 2 diabetes medicine, many of the panelists objected to the two complicated pen devices the company is proposing to use to administer the drug – calling for them to be redesigned.

You may also be interested in...



Panel Back's Novo's Diabetes Combo, But Will The Market?

An FDA advisory panel unanimously backed approval of Novo Nordisk AS' fixed-dose combination of Victoza (liraglutide) and Tresiba (insulin degludec), but if the agency approves the drug, it will be facing a market full of competitors and several other new products coming down the pike.

Sanofi's 2-Pen Diabetes Combo Perplexes FDA

Sanofi SA's strategy of using two pen injectors for its fixed-ratio combination that combines its experimental glucagon-like peptide-1 receptor agonist lixisenatide with its US-approved diabetes drug Lantus (basal insulin glargine) has the FDA perplexed and concerned about the potential for adverse events and medication errors.

FDA On Novo's Diabetes Combo: It's Complicated

A May 24 advisory panel meeting is critical for Novo Nordisk's effort to convince the FDA to approve the Danish company's fixed-dose combination diabetes drug IDegLira – which unites Victoza (liraglutide) with Tresiba (insulin degludec) – but regulators questioned the firm's trial design.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel